Stoked! Weed May Light The Flame For A Roll In The Hay

Many states permit the use of medical marijuana. Now there’s evidence that pot might work as “marital marijuana,” revving up sex drives in both men and women.

The exact nature of the cannabis-coitus connection remains unresolved, but researchers attempted to cut through the haze with a new study published in the November issue of the Journal of Sexual Medicine.

It showed that people who toke up are more likely to get down (and dirty).

It actually doesn’t matter who’s partaking — male or female, single or married, childless and carefree, or busy breeder. Among all demographic and ethnic groups, those who smoke weed reported having more sexual intercourse than those who don’t, the research shows.

New Jersey sues OxyContin maker, links marketing to opioid crisis

(Reuters) – New Jersey on Tuesday sued Purdue Pharma LP, accusing the OxyContin maker of contributing to the state’s opioid crisis through deceptive marketing to doctors and patients, including the elderly and the “opioid-naive.”

FILE PHOTO: A pharmacist holds prescription painkiller OxyContin, 40mg pills, made by Purdue Pharma L.D. at a local pharmacy, in Provo, Utah, U.S. on April 25, 2017. REUTERS/George Frey/File Photo

Christopher Porrino, the New Jersey attorney general, faulted what he called a decade-long marketing campaign of ”almost inconceivable callousness and irresponsibility, and said Purdue downplayed the risks of opioids and exaggerated their benefits in the pursuit of profit.

U.S. states allege broad generic drug price-fixing collusion

WASHINGTON (Reuters) – A large group of U.S. states accused key players in the generic drug industry of a broad price-fixing conspiracy, moving on Tuesday to widen an earlier lawsuit to add many more drugmakers and medicines in an action that sent some company shares tumbling.

A person holds pharmaceutical tablets and capsules in this picture illustration. REUTERS/Srdjan Zivulovic

The lawsuit, brought by the attorneys general of 45 states and the District of Columbia, accused 18 companies and subsidiaries and named 15 medicines. It also targeted two individual executives: Rajiv Malik, president and executive director of Mylan NV, and Satish Mehta, CEO and managing director of India’s Emcure Pharmaceuticals.

Medicare Open Enrollment: Peace of Mind with Medicare Coverage

Having health insurance with covered benefits that you can count on can bring peace of mind. If you have Medicare, you get benefits like:

  • A host of preventive tests and screenings — including cancer screenings — most at no cost to you
  • A discount of 65% on covered brand-name drugs with Part D if you hit the prescription drug coverage gap (“donut hole”)

Medicare also covers a yearly “wellness visit”. This is a great chance to sit down with your doctor and talk about your needs — and address small health concerns before they become big ones. You can keep track of your preventive services and get reminders for them at

Timeline: Insulin Market Under Scrutiny

The price of lifesaving diabetes drugs has skyrocketed over the past decade. And patients aren’t the only ones who have noticed. Five states and a federal prosecutor are demanding information from insulin manufacturers and the pharmaceutical industry’s financial middlemen.

Below, we detail when legal action related to insulin drugs began, with links to documents.

March 2016

The U.S. Attorney’s Office for the Southern District of New York launches the first of several civil investigative demands (CIDs), beginning with Sanofi and Novo Nordisk.

Investor group presses U.S. drug companies on opioid controls

BOSTON (Reuters) – U.S. shareholder activists are addressing a soaring death toll from opioid drug abuse, asking companies that make and distribute the painkillers to review the risks their businesses could face from their role in the sector.

FILE PHOTO: A used needle sits on the ground in a park in Lawrence, Massachusetts, U.S., May 30, 2017, where individuals were arrested earlier in the day during raids to break up heroin and fentanyl drug rings in the region, according to law enforcement officials. REUTERS/Brian Snyder/File Photo

Leaders of a 30-fund group that includes state pension officials and religious and labor organizations plan to reveal on Monday they have begun filing shareholder resolutions at 10 companies, including distributors AmerisourceBergen Corp (ABC.N) and Cardinal Health Inc (CAH.N) and manufacturers Johnson & Johnson (JNJ.N) and Insys Therapeutics (INSY.O).

Cancer-drug setback sends Merck shares down again

NEW YORK (Reuters) – A setback for Merck & Co’s (MRK.N) key cancer drug sent the drugmaker’s stock swooning on Monday for a second straight session, putting the shares on track for their biggest two-day decline in more than eight years.

The logo of Merck is pictured in this illustration photograph in Cardiff, California April 26, 2016. REUTERS/Mike Blake/Illustration/File Photo

Late on Friday, Merck withdrew an application for European use of its flagship drug Keytruda as an initial, or first-line, treatment for advanced lung cancer in combination with chemotherapy, raising questions about future sales.

Could marijuana be an aphrodisiac?

By October 29, 2017

A new study is the first to show that regular use of marijuana or cannabis is linked to having more sex. The study by the Stanford researchers assessed the use of marijuana and frequency of sexual intercourse among participants in the United States. Results were unprecedented.

The study was published online on the 27th of October 2017 in the Journal of Sexual Medicine.

Cannabis / Marijuana Leaves. Image Credit: OpenRangeStock / Shutterstock

Cannabis / Marijuana Leaves. Image Credit: OpenRangeStock / Shutterstock

Celltrion Healthcare announces results from phase III CT-P13 switching trial in patients with Crohn’s disease

October 30, 2017

Today at the 25th United European Gastroenterology Week Congress, Celltrion Healthcare presented data from the phase III, randomized controlled, switching trial comparing CT-P13 and reference infliximab. The data showed comparable efficacy and safety between all treatment groups (maintained and switched) in patients with moderate to severe Crohn’s disease (CD) up to one year.